Valproic acid-induced pancreatitis in an adult

Bruno Lopes dos Santos¹, Regina Maria França Fernandes², Fábio Fernandes Neves³

Idiosyncratic reactions to drugs are adverse effects not straightly related with pharmacodynamic mechanisms of the drug and they can take place on unpredictable way by abnormal interaction between the drug and the organism, usually mediated by immunologic or cytotoxic effects triggered by the drug or its metabolites¹. Even being responsible for 6-10 % of all the adverse reactions to drugs, the idiosyncratic effects can be important sources of morbidity and mortality, mainly in children¹. The anti-epileptic drugs (AED) also can cause adverse effects by these mechanisms, which impairs the seizure control and obliges the physician to use second line drugs. A study in epileptic patients showed that 10 to 27 % stopped their first treatment with AED on account of the adverse effects, being several of them idiosyncratic¹. Valproic acid (VPA) is a carboxylic acid used as anti-epileptic in idiopathic and symptomatic generalized epilepsies and in some cases of symptomatic focal epilepsies, as well as for trigeminal neuralgia, migraine and bipolar disorders⁷. Its mechanism is unknown, however it is probably associated with the metabolism of the neurotransmitter GABA. The toxic effects it provokes can be dose-dependent or idiosyncratic. There are several VPA-related idiosyncrasies, being the most noteworthy alopecia, bone marrow aplasia, immune-mediated hepatotoxicity and pancreatitis¹. The acute pancreatitis is a disease of several etiologies, sometimes caused by use of determined drugs. The pancreatitis provoked by VPA is a rare entity, with estimated incidence of 1:40000⁵, occurring mainly during the first year of treatment or after increase in the dose, with higher incidence in young individuals, in polytherapy (mainly with carbamazepine, phenytoin, phenobarbital and some benzodiazepines), with chronic encephalopathies and in dialysis treatment¹⁴. The supposed pathogenic mechanism is by direct toxic effect of free radicals in the membranes of the pancreatic cells²,³,⁵,⁶. The onset can be a slight asymptomatic hyperamylasemia up to a fatal necrohemorrhagic pancreatitis⁴, and the mortality varies from 17 to 20 %, with many complications in the non-lethal cases (pseudocysts, infections, septic shock, chronic pancreatitis, endocrine pancreatic insufficiency)². The treatment is based on the immediate withdrawal of the drug, general clinical support and specific treatment of the possible complications.

We present the case of a patient who, in less than 2 months of treatment with appropriate dose of VPA, evolved to pancreatitis.

CASE

A male 34 years-old, white, resident at Ribeirão Preto, tattooist, single, with a past history of depressive episode, began to have complex partial seizures by 25 years of age, in increasing frequency. After the diagnosis of focal epilepsy, he was put on VPA, in dose of 16.5 mg/kg/day, increasing up to 25 mg/kg/day after 25 days as the initial dose. After such increase in daily dose, he felt a mild epigastric pain, improved by symptomatic medicines, however on a progressive pattern. After 15 days using VPA at 25 mg/kg/day,

PANCREATITE AGUDA EM ADULTO INDUZIDA PELO ÁCIDO VALPRÓICO

Ribeirão Preto School of Medicine, University of São Paulo, São Paulo SP, Brazil; ªPhysician Resident in Neurology, Department of Neurosciences and Behaviour Sciences; ªNeurologist and Associated Professor, Department of Neurosciences and Behaviour Sciences; ªEmergencist Physician, Department of Internal Medicine.
there was worsening of epigastric pain with became very intense, enhancing after food, irradiating to the dorsal area of trunk, associated with vomiting and anorexia. He was admitted in an emergency room, with serum amylase of 1682 UI/L, being transferred to our service under the suspicion of acute pancreatitis. There was no history of ethylic abusive drinking, abdominal traumas nor recent infectious disorders. On physical examination, he was afebrile, normal vital signs and diffuse abdominal pain, without signs of peritonitis. Laboratorial workup showed leukocytosis, serum amylase of 1743 UI/L, normal arterial blood gas analysis, without scoring in the Ranson’s severity criteria in the admission and APACHE II of 4 points. Clinical measures for acute pancreatitis were provided; he was put off VPA and started on carbamazepine. On abdominal ultrasound, showed no alteration in the biliary tract, with some increase in pancreatic volume and small ascitis. Abdominal CT scan showed a diffuse increase in pancreas volume, presence of peripancreatic liquid, slight ascitis and a small pleural effusion on the left, classified as edematous acute pancreatitis Balthazar B. The lipid profile was normal, with low serum VPA level and normal plasma ammonia. HIV and hepatitis serologic tests were negative. The patient went on well, without recurrence of the abdominal pain with fasting, with no scoring in Ranson’s criteria after 48 hours. Oral diet was gradually reintroduced with good acceptance and no worsening of the symptoms. He was discharged in the 6th day of hospitalization, with serum amylase of 341 UI/L.

**DISCUSSION**

The first cases of acute pancreatitis associated to VPA were reported in 1979, by Bataladen et al. and Camfield et al., with several sporadic cases being published subsequently. There are 2 cases described in the Latin America, all in Brazil, the first one in 1986, by Tannhauser Barros et al., and the other in 1998 by Munhoz et al. Most of the reported cases happened in children, corresponding to 13% of all cases of acute pancreatitis of childhood. From the first description, some literature reviews have been done, with 106 cases described until the moment of the finishing of this report, however there are doubts about these numbers.

In our case, the age of the patient is compatible with the most affected age group in adults, but the patient was not using polytherapy and the disease developed in only 40 days after the beginning of the drug (as seen by Biour et al., there is a case with 1 day of use of VPA), in the appropriate dose (25 mg/kg/day), with ascending serum level (18.52 mg/dL), the lowest level of all reported in the literature, reinforcing the idiosyncratic nature of this adverse reaction. It is expected that this complication related to a widely used drug might have an incidence much higher than reported in the literature, because of undernotification, and physicians who prescribe AED on a daily basis, and should be aware in order to recognize the first signs of this disorder.

**REFERENCES**